Age, dose, and environmental temperature are risk factors for topiramate-related hyperthermia.
Ziad
El Khoury
el K
Department of Pediatrics, Director, American University of Beirut Medical Center, Beirut, Lebanon.
Rahi
Amal C
AC
Hamdan
Sahar Abu
SA
Mikati
Mohamad A
MA
D000367:Age Factors; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects*; D001831:Body Temperature / Q000187:drug effects / Q000502:physiology; D015984:Causality; D002648:Child; D002675:Child, Preschool; D002980:Climate; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions / Q000502:physiology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004777:Environment; D005260:Female; D005334:Fever / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D005500:Follow-Up Studies; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007223:Infant; D007861:Lebanon; D008297:Male; D011446:Prospective Studies; D012307:Risk Factors; D013696:Temperature; D000077236:Topiramate
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose